

Appendix A: Conflict of Interest Disclosure Form

CADTH Expert Committee and Panel Members

I have read and understood the conflict of interest (COI) guidelines and I agree to be bound by the obligations contained therein. I understand that it is my responsibility to report to CADTH any real, potential, or perceived conflicts of interest as defined in the COI guidelines, and to disclose the information requested in the COI guidelines.

As a member of a CADTH committee or panel, I also understand that a summary of my expertise, experience, affiliations, and conflict of interest declaration will be publicly available on the CADTH website and in all CADTH publications to which I have contributed in an advisory (i.e., have made recommendations) or authorship role.

I understand that the information disclosed will be retained on file by CADTH.

I have reviewed my investments, affairs, affiliations, activities, and interests, and have accurately completed the attached Schedules 1, 2, and 3.

I hereby certify that I have disclosed all relevant information with respect to any matter involving a Party that may place me in a real, potential, or a perceived conflict of interest situation. Except as otherwise disclosed in the attached Schedules 1, 2, and 3, I declare that I have no conflict of interest to report as defined in the COI guidelines.

I undertake and promise to inform CADTH of any change in circumstances that may create a conflict of interest as soon as it is known to me.

Date	Print Name	Signature

Conflict of Interest Disclosure Form — Schedule 1

(Reference: COI guidelines, section 5.3)

Disclosures are required under section 5.3 of the *Conflict of Interest Guidelines* for those activities or interests involving any Party during the past three years that benefited the Member or related person, particularly as the activities relate to the following areas (add pages as necessary):

Name of Party (See section 2.2 for definition.)	Drug, Technology, or Topic Involved and Year of Funding

^a Other gifts/funding/honoraria (please provide details):

I do not have declarations for Schedule 1.

April 25 2019

Michael Crump

Date

Print Name

Conflict of Interest Disclosure Form – Schedule 2

(Reference: COI guidelines, section 5.4)

Disclosures are required under section 5.4 of the *Conflict of Interest Guidelines* for those activities or interests involving any Party during the past three years that benefited the Member or related person, particularly as the activities relate to the following areas (add pages as necessary):

Name of Party (See section 2.2 for definition.)	Drug, Technology, or Topic Involved and Year of Funding
Jansen Inc	Ibrutinib, 2016
Servier Canada Inc	Pralatrexate, 2017
Gilead Sciences/ Kyte Pharma	Axicabtagene ciloleucel (CAR T cell therapy) 2018

^b Payments as advisor/consultant: please provide details:

Ibrutinib: role in primary therapy and for relapse of CLL
 Pralatrexate: pre-filing meeting with Health Canada, to describe current treatment environment in Canada for T cell lymphomas
 CAR-T cell therapy: possible role of CAR-T cell therapy in relapsed and refractory diffuse large B cell lymphoma in Canada

I do not have declarations for Schedule 2.

April 25 2019

Michael Crump

Date

Print Name

Signature

Conflict of Interest Disclosure Form – Schedule 3

(Reference: COI guidelines, section 5.5)

List those activities, affiliations, or interests involving a Party in the past three years (not already listed in Schedules 1 and 2) that may affect or compromise, or appear to affect or compromise, the Member's objectivity, fairness, or professional judgment (as outlined in Section 5.5.1). See list of examples in Section 5.5.2.

Name of Party (See section 2.2 for definition.)	Nature or Description of Activities or Interests (See section 5.5.2.)
Roche Canada	Phase I-II Clinical trial of Ro 708-2859 in relapsed NHL: clinical trial support (no personal or salary support for me as an investigator)
Celgene	ROBUST phase III trial of lenalidomide in large B cell lymphoma: clinical trial support (no personal or salary support for me as investigator)

List those activities, affiliations, or interests involving a Party with whom the Member has a potential or pending future commitment (as outlined in Section 5.5.3). Provide details on the nature of the commitment.

Name of Party (See section 2.2 for definition.)	Nature and Timing of the Future Commitment

I do not have declarations for Schedule 3.

April 25 2019

Michael Crump

Date

Print Name